Third quarter IBO Life Science Index sales grew 7.0% on a reported and currency-neutral basis, to $3,581 million. Operating profit climbed 12.7% to $762 million. Index results were elevated by Illumina’s performance but partially offset by Bruker. Excluding these two companies, organic sales and adjusted operating profit grew 5.4% and 6.7%, respectively. Based on continuing […]
Fiscal fourth quarter sales ending September 30 for Brooks Automation’s Life Science Systems (LSS) segment climbed 77.4% to $20.0 million to account for 16% of company sales. Excluding the acquisition of Matrical (see IBO 7/31/13), sales grew 63% driven by demand for automated sample-management systems and services. Including the acquisition, Product and Service revenue grew […]
Encouraging economic data and corporate-earnings reports lifted US equity markets to new highs in November. Following 4.6% growth in the second quarter, US third quarter GDP growth was revised upwards 40 basis points to 3.9% due to strong consumer spending. However, weaker-than-expected capital-goods orders and a spike in US jobless claims, coupled with slow manufacturing […]
St. Louis, MO 11/3/14; Washington, DC 11/3/14; Washington, DC 11/25/14—Sigma-Aldrich has announced that it will hold a special stockholder meeting on December 5 to vote on Merck KGaA’s proposed acquisition of the company (see IBO 9/30/14). In addition, Sigma announced an agreement to settle one of three putative class-action suits brought by shareholders against the […]
Oberkochen, Germany 11/13/14—ZEISS has announced that it plans to reduce costs in its Microscopy business, according to a Google translation of a German press release from the company. The aim is to save at least $100 million in the medium term and to increase profitability and competitiveness. Three-quarters of the savings will come from fixed […]
Santa Clara, CA 11/3/14; Santa Clara, 11/20/14—Agilent Technologies has announced that beginning with the current quarter, the first quarter of its fiscal year 2015, it will report in three new divisions: the Life Sciences and Applied Markets Group (LSAG), the Diagnostics and Genomics Group (DGG), and the Agilent CrossLab Group (see IBO 9/30/14). “The organization […]
The calendar-year third quarter produced mixed financial results for the revenues of major publicly held analytical instrument and laboratory-product businesses. Growth in selected clinical and pharmaceutical end-markets offset continued weakness in industrial end-markets and China. Companies forecast little change for the next quarter. Revenues for the seven businesses whose results are detailed on pages 9–11 […]
This month, Eurostat released the first estimates of 2013 R&D expenditures of the 28 EU member states. Also provided was a breakdown of expenditures by sector, and R&D intensity (R&D expenditure as a percentage of GDP) for each country. The report of R&D intensity is the first using the new European System of Accounts (ESA). […]
To augment IBO’s coverage of quarterly financial results, IBO will now provide sidebar summaries of results for companies not in the Sales Indexes. Third quarter FEI sales grew 4.2%, 3.5% organically, to $218.5 million (see page 12), with acquisitions contributing 0.9% and currency lowering sales 0.2%. Industry sales grew 3.3%, 1.7% organically, to account for […]
The purchase prices of certain acquisitions are not announced initially but are later announced in SEC filings. Below are acquisitions whose price was subsequently disclosed.
Pay Invoice
Latest Blogs
-
New Report Details Higher Education Science R&D Spending
February 27, 2026 3:23 pm
-
Single Use Leads Bioreactor Market Growth
December 30, 2025 6:04 pm
Sitemap
Your Data and Privacy
About Us
IBO (Instrument Business Outlook) is a twice-monthly newsletter aimed at providing decision-makers with the latest and most complete information available on the life science and analytical instrument industry, and lab product markets. IBO delivers the latest curated industry news, information and trends, as well as SDi data and analysis to deliver the maximum in industry insight with a minimum time investment for executives and investors.
